Form 10Q Galera Therapeutics Inc For: 13 August
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
TG Therapeutics Inc (TGTX)
TG Therapeutics Inc stock price live, this page displays NASDAQ TGTX stock exchange data. View the TGTX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the TG Therapeutics Inc real time stock price chart below.
What Is the TG Therapeutics Inc Stock Price Today?
The TG Therapeutics Inc stock price today is 28.53.
What Is the Stock Symbol for TG Therapeutics Inc?
The stock symbol for TG Therapeutics Inc is ""TGTX.""
What Stock Exchange Does TG Therapeutics Inc Trade On?
TG Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is TG Therapeutics Inc a Good Stock to Buy?
Determining whether TG Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TGTX quote. (ISIN: US88322Q1085)
What Is the TG Therapeutics Inc Stock Price Today?
The TG Therapeutics Inc stock price today is 28.53.
What Is the Stock Symbol for TG Therapeutics Inc?
The stock symbol for TG Therapeutics Inc is ""TGTX.""
What Stock Exchange Does TG Therapeutics Inc Trade On?
TG Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is TG Therapeutics Inc a Good Stock to Buy?
Determining whether TG Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TGTX quote. (ISIN: US88322Q1085)
Fair Value
An estimate of a TG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.50
29.80
52 wk Range
21.11
46.48
TGTX Scorecard
Full Analysis
Net income is expected to grow this year
TGTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a TG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.5029.80
52 wk Range
21.1146.48
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TGTX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a TG's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
40.50
Upside
+41.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Form 10Q Galera Therapeutics Inc For: 13 August
- Investing.com
- Form 8K TG Therapeutics Inc For: 4 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
TG Therapeutics Inc Company Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
TG Therapeutics Inc Earnings Call Summary for Q2/2025
- TG Therapeutics Q2 2025 EPS of $0.17 missed forecast by 10.53%, while revenue of $141.1M beat expectations by 2.69%
- Company raised full-year revenue guidance to $575M, driven by 91% YoY increase in U.S. net product revenue from BREONVY
- Stock fell 7.48% in pre-market trading despite revenue beat, reflecting investor concerns over EPS miss
- Development of subcutaneous BREONVI and azurecel therapy for progressive MS highlight company's focus on innovation
- Management confident in BREONVI's potential to become multibillion-dollar brand in relapsing MS market
Last Updated: 04/08/2025, 14:30
Read Full TranscriptCompare TGTX to Peers and Sector
Metrics to compare | TGTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTGTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 68.8x | −4.7x | −0.6x | |
PEG Ratio | −1.59 | −0.21 | 0.00 | |
Price/Book | 15.1x | 2.9x | 2.6x | |
Price / LTM Sales | 9.2x | 19.3x | 3.3x | |
Upside (Analyst Target) | 59.9% | 162.6% | 39.0% | |
Fair Value Upside | Unlock | 3.6% | 4.9% | Unlock |
Analyst Ratings
6 Buy
1 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 40.50
(+41.96% Upside)
Earnings
Latest Release
Aug 04, 2025
EPS / Forecast
0.17 / 0.19
Revenue / Forecast
141.10M / 137.40M
People Also Watch
FAQ
What Stock Exchange Does TG Trade On?
TG is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for TG?
The stock symbol for TG is "TGTX."
What Is the TG Market Cap?
As of today, TG market cap is 4.18B.
What Is TG's Earnings Per Share (TTM)?
The TG EPS (TTM) is 0.41.
When Is the Next TG Earnings Date?
TG will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is TGTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has TG Stock Split?
TG has split 3 times.
How Many Employees Does TG Have?
TG has 370 employees.
What is the current trading status of TG (TGTX)?
As of 26 Aug 2025, TG (TGTX) is trading at a price of 28.53, with a previous close of 29.45. The stock has fluctuated within a day range of 28.50 to 29.80, while its 52-week range spans from 21.11 to 46.48.
What Is TG (TGTX) Price Target According to Analysts?
The average 12-month price target for TG is USD40.5, with a high estimate of USD53 and a low estimate of USD11. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +41.96% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.